secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hyperliquid Strategies Inc (PURR)
CIK:        0002078856
Form:       8-K/A
Filed at:   2026-02-18T23:59:59+00:00
Accession:  0001193125-26-055449
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hyperliquid Strategies files audited Sonnet FY2025 financials after combo
-------------------------------------------------------------------------

- Sonnet's audited financials for FY ended Sep 30, 2025 filed; pro forma data included.
- Market value of Sonnet common equity held by non-affiliates: $4.15M as of Mar 31, 2025 ($1.34/share).
- Sonnet is a clinical-stage oncology biotech with FHAB platform; lead SON-1010 in solid tumors.
- Business combination closed Dec 2, 2025; Hyperliquid now wholly owns Sonnet.
- Sonnet has history of operating losses and requires significant additional capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2078856/000119312526055449/0001193125-26-055449-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2078856/000119312526055449/purr-20251202.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-055449

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer